High Tacrolimus Variability Doubles Graft Loss Risk in Kidney Transplants
A new meta-analysis reveals that high variability in tacrolimus levels significantly increases the risk of graft loss and rejection in kidney transplant patients.
High tacrolimus intrapatient variability (IPV) correlates with more than double the risk of graft loss.
The study analyzed data from 11,647 kidney transplant recipients, highlighting the need for standardized monitoring.
Further research is necessary to establish tacrolimus IPV as a reliable clinical tool.
A recent systematic review and meta-analysis has found that high variability in tacrolimus levels among kidney transplant recipients is linked to a significantly increased risk of graft loss and rejection. The analysis, which included data from 11,647 adult patients, underscores the importance of monitoring tacrolimus exposure to improve long-term transplant outcomes.
The researchers aimed to clarify the relationship between tacrolimus intrapatient variability (IPV) and clinical outcomes by reviewing 10 cohort studies published up to October 2025. The primary focus was on death-censored graft loss, with a sophisticated random effects meta-analysis employed to account for variations across studies. The findings revealed that patients with high tacrolimus IPV faced more than twice the risk of graft loss, with a hazard ratio of 2.13, and a similar increase in rejection risk, with a hazard ratio of 2.05.
Despite the alarming statistics, the analysis indicated considerable variability in graft loss rates among the studies, with an I² value of 69.3%. In contrast, the heterogeneity for rejection was notably lower at 0.0%, suggesting a more consistent relationship across the studies for this outcome. The prevalence of high tacrolimus IPV varied widely, ranging from 11% to 69%, which may be attributed to differences in measurement methods and assessment periods used in the studies.
These findings suggest that monitoring tacrolimus IPV could be crucial for identifying kidney transplant recipients who are at a heightened risk of adverse outcomes. However, the researchers caution that the observed associations do not confirm that variability directly causes these outcomes. They stress the need for standardized measurement techniques and validated thresholds before tacrolimus IPV can be reliably used in clinical practice.
Looking ahead, healthcare professionals involved in kidney transplantation are encouraged to explore tacrolimus variability further. Establishing consistent measurement approaches and understanding the predictive value of IPV may enhance the assessment of transplant outcomes and ultimately improve patient care.
